SEC Filing Summary: Senti Biosciences Holdings, Inc. (SNTI)
Business Context and Reporting Period
This Form 8-K was filed on May 14, 2026, by Senti Biosciences Holdings, Inc., a Delaware corporation listed on The Nasdaq Capital Market. The filing serves as a current report announcing financial results for the quarter ended March 31, 2026, and updates regarding clinical data and regulatory interactions for the product SENTI-202.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes and Operational Updates
- Financial Results: The Company announced results for the quarter ended March 31, 2026, via a press release (Exhibit 99.1).
- Clinical and Regulatory: The Company announced specific clinical data and regulatory interactions related to its product SENTI-202 via a separate press release (Exhibit 99.2).
Guidance, Outlook, and Risks
The provided text does not contain specific guidance, outlook figures, management commentary, or risk factors. The filing explicitly states that the information in Item 2.02 and the attached exhibits is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings.
Investor Verification Checklist
- Review Exhibit 99.1 for specific Q1 2026 financial figures (revenue, net loss, cash position).
- Review Exhibit 99.2 for details on the SENTI-202 clinical data and the nature of regulatory interactions.
- Verify the Company's cash runway and burn rate based on the full press release content.
- Confirm any updated timelines for SENTI-202 regulatory submissions or approvals.